Compare LOCL & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | FEMY |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | United States |
| Employees | 286 | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 22.4M |
| IPO Year | 2021 | 2021 |
| Metric | LOCL | FEMY |
|---|---|---|
| Price | $0.96 | $1.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 20.3K | ★ 92.3K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.33 | 44.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,365,000.00 | $2,293,313.00 |
| Revenue This Year | $93.32 | N/A |
| Revenue Next Year | $25.13 | $328.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 26.82 | ★ 40.77 |
| 52 Week Low | $0.90 | $0.29 |
| 52 Week High | $3.35 | $6.29 |
| Indicator | LOCL | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 33.87 |
| Support Level | N/A | $0.40 |
| Resistance Level | $1.20 | $3.21 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 17.55 | 32.73 |
Local Bounti Corp is a controlled environment agriculture company. The business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides. The products of the company include living lettuce, leafy greens, herbs, and others.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.